Free Republic

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, research suggests A new meta-analysis suggests doctors and patients can avoid unnecessary prostate biopsies by combining MRI of the prostate findings with prostate-specific antigen (PSA) density. To doctors, clinically significant prostate cancer (csPCa) is prostate cancer that has a high chance of threatening a patient's life. MRI of the prostate can provide some of this information. Still, a biopsy is traditionally needed to determine how aggressive the cancer cells look. This study tested a new approach: combining MRI-based prostate imaging...

New urine-based test looks at 18 genes and was specifically developed to pick out those cancers that need immediate treatment over the slow-growing type. Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment. The test, called MyProstateScore2.0, or MPS2, looks at 18 different genes linked to high-grade prostate cancer. In multiple tests using urine and tissue samples from men with prostate cancer, it successfully identified...

The largest study to date investigating a single invitation to a PSA blood test to screen for prostate cancer has found it had a small impact on reducing deaths, but also led to overdiagnosis and missed early detection of some aggressive cancers. The CAP trial, published in the Journal of the American Medical Association (JAMA) and carried out by researchers from the universities of Bristol, Oxford and Cambridge, involved over 400,000 men aged 50-69. Just under half received a single invitation for a PSA test as part of the trial. After following up for 15 years, there was a small...

Men who get the COVID-19 vaccinations are being warned by a urologist in Palm Beach County, Florida, that they may cause a spike in the results on one medical test.It's Dr. Diego Rubinowicz who said, in a report by CBS12, that it is the PSA levels for men who are being tested, often routinely, for prostate cancer, that are affected.The report explained prostate cancer is a common cancer for men, with a quarter of a million cases or thereabouts diagnosed in 2021.But the doctor said he's been seeing elevated PSA test levels in men who got vaccinations, not necessarily related...

Clinical Context Few topics in the field of preventive medicine are contentious as prostate cancer screening. Widespread screening for prostate cancer has had a remarkable effect on the epidemiology of this tumor, as demonstrated in a study by Welch and Albertsen published in the October 7, 2009, issue of the Journal of the National Cancer Institute. Their study found that the introduction of routine prostate cancer screening led to approximately 1.3 million more men being diagnosed with prostate cancer in the United States alone. Men younger than 60 years accounted for most of this surge in cases. The authors estimated...

A day after a government panel said that healthy men should no longer get screened for prostate cancer, some doctors’ groups and cancer patients’ advocates began a campaign to convince the nation that the advice was misguided. Their hope is to copy the success of women’s groups that successfully persuaded much of the country two years ago that it was a mistake for the same panel, the United States Preventive Services Task Force, to recommend against routine mammograms for women in their 40s.

Transcript JEFFREY BROWN: Men shouldn't be routinely tested for prostate cancer. That was the recommendation today of an influential government panel that looked at whether PSA tests can extend lives by detecting cancer earlier.The tests measure levels of a protein made in the prostate. But the U.S. Preventive Services Task Force said they do more harm than good, including unnecessary biopsies, surgery, radiation and impotence. The panel concluded that -- quote -- "The common perception that early detection prolongs lives is not supported by the scientific evidence."Last year, more than 217,000 American men were diagnosed with prostate cancer; 32,000 died...

The U.S. Preventive Services Task Force, the group that told women in their 40s that they don't need mammograms, will soon recommend that men not get screened for prostate cancer, according to a source privy to the task force deliberations. The task force is set to recommend a "D" rating for prostate specific antigen, or PSA, testing. Such a rating means "there is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits," according to the group's website. The task force is set to propose this recommendation Tuesday, and then allow for...

The PSA test, used to screen men for detecting prostate cancer has been declared all but useless by a pioneer in the procedure. Stanford University School of Medicine professor Dr. Thomas Stamey said "The PSA era is over in the United States." Dr. Stamey and colleagues examined more than 1,300 prostate tissue samples removed by urologists at Stanford over the past 20 years. Researchers divided the data from the samples into four five-year periods between 1983 and 2004. They found a substantial decrease in the connection between PSA levels and the amount of prostate cancer over time. In the first...